Related by context. All words. (Click for frequent words.) 72 Initiates Voluntary Recall 69 Announces Voluntary Recall 69 Announces FDA Clearance 68 Completes Transition 68 Initiates Clinical Trial 67 Board Unanimously Rejects 67 Issues Clarification 67 Receives Favorable 67 Completes Tender Offer 67 Licenses Novel 67 Completes Previously Announced 67 Board Authorizes 67 Receives Approvable Letter 67 Announces Stockholder Approval 67 Gets FDA Clearance 66 Expands Scope 66 FDA Warns 66 Psoriasis Drug 66 Consummates 66 Updates Guidance 66 Epilepsy Drug 66 Extends Tender Offer 66 Arthritis Drug 66 Receives Favorable Ruling 66 Explore Strategic Alternatives 66 Q2 Loss Narrows 66 Gets Clearance 66 Announce Definitive Agreement 65 Completes Conversion 65 Submits Biologics License Application 65 Guidelines Issued 65 Files Shelf Registration Statement 65 STERIS Corporation Announces 65 Receives Unsolicited 65 Anemia Drugs 65 Milestone Achieved 65 Drug Fails 65 Initiates Enrollment 65 Submits NDA 65 Revises Guidance 65 Finalizes Sale 65 Completes Patient Enrollment 65 Announces Divestiture 65 Receives Milestone Payment 65 Expands Recall 65 Completes Enrollment 65 Enters Definitive Agreement 65 Recall Issued 65 Reduces Risk 65 Study Shows Benefits 65 Recall Expanded 65 Restates Earnings 65 Completes Divestiture 65 Amends Agreement 65 Reaffirms Outlook 65 Regains Nasdaq 65 Receives Notification 65 Receives Approvals 65 Provides Update Regarding 65 Receives Subpoena 65 Reacquires 65 Announces Postponement 65 Lupus Drug 65 Permanent Injunction Against 65 Obtains Approval 65 Q2 Loss Widens 65 Successfully Completes Tender Offer 65 Proves Successful 65 Receives Commitment 64 FDA Clears 64 Files Voluntary 64 Q4 Loss Narrows 64 Strengthens Balance Sheet 64 Begins Clinical Trial 64 Announces Cancellation 64 4Q Loss Widens 64 Voluntarily Recalls 64 Voluntarily Withdraws 64 Regains NASDAQ 64 Receives Orphan Drug Designation 64 Announces Definitive Agreement 64 Announces Spin Off 64 Completes Buyout 64 FDA Okays 64 Completes Refinancing 64 FDA Approvals 64 Announces Restatement 64 Explores Strategic Alternatives 64 Identifies Potential 64 Transplant Patients 64 Announces Organizational Changes 64 Files IND 64 Posts Wider Loss 64 Extends Maturity 64 Hip Implants 64 Provides Guidance 64 Antidepressants Linked 64 NDA Submission 64 Settles Litigation 64 Terminates Contract 64 Announces Successful Completion 64 Submits Application 64 Achieves Significant 64 Q4 Loss Widens 64 Resolve Allegations 64 Resolves Dispute 64 Secures Patent 64 FDA Panel Recommends 64 Submits Response 64 Announces Repurchase 64 SABESP Announces 64 Milestone Payment 64 Device Maker 64 Appoints Experienced 64 Restructures Debt 64 Announce License Agreement 64 Completes Merger With 64 Flamel Technologies Announces 64 Q3 Adj 64 Rat Poison Found 64 Q2 Adj 64 Announces Consummation 64 Voluntarily Withdraw 64 Q3 Loss Narrows 64 Flexpoint Announces 64 Receives Shareholder Approval 64 Q4 Profit Decreases 64 Purported Class 64 Regains Full 64 Unsolicited Proposal From 64 Revises FY# Outlook 64 Gets Subpoena 64 Signs Merger Agreement 64 Organizational Changes 63 TriCo Bancshares Announces 63 Expands Capabilities 63 Q1 Loss Widens 63 AVI BioPharma Announces 63 Seeks Approval 63 Surpasses Estimates 63 3Q Loss Narrows 63 Levels Linked 63 Q1 Profit Decreases 63 Drug Shows Promise 63 Terminates Agreement 63 Awarded Patents 63 Completes Restructuring 63 Clinical Trial Data 63 Q1 Loss Narrows 63 Achieves Milestone 63 Backs FY# Outlook 63 Realty Trust Announces 63 Completes Transaction 63 Temporarily Suspends 63 Begins Shipment 63 Contaminated Heparin 63 Announces Recapitalization 63 BioSante Pharmaceuticals Announces 63 Announce Merger Agreement 63 PPD Declares 63 Closes Merger 63 Drug Maker 63 Lowers Guidance 63 PDL BioPharma Announces 63 Study Demonstrates 63 Announces Effective Date 63 Suspends Quarterly Dividend 63 Receives FDA Clearance 63 Q3 Loss Widens 63 Files Shelf Registration 63 Consolidates Operations 63 Extend Partnership 63 Reduces Debt 63 Finalizes Purchase 63 ViRexx Announces 63 Wins Approval 63 Demonstrates Significant 63 Issues Recall 63 Narrows 4Q Loss 63 Settle Litigation 63 Issues Guidance 63 Nationwide Voluntary Recall 63 Suspends Dividend 63 Makes Unsolicited Bid 63 Files Patent Application 63 Continues Commitment 63 Completes Reorganization 63 Funds Declare Dividends 63 Winmark Corporation Announces 63 Receive Milestone Payment 63 Finalizes Acquisition 63 Receives Stockholder Approval 63 Q1 Adj 63 Improves Survival 63 Prompts Recall 63 Posts 3Q Profit 63 Sinks Lower 63 Reclassifies 63 Discontinues 63 Headwaters Incorporated Announces 63 Plans Job Cuts 63 Shareholders Approve Sale 63 Sells Portion 63 Over Allotment Option Exercised 63 Q2 Profit Decreases 63 Shareholders Approve Acquisition 63 Hip Implant 63 Blood Pressure Drug 63 2Q Loss Widens 63 Sets Quarterly Dividend 63 Stockholders Approve Merger 63 Shareholder Lawsuits 63 Medicure Announces 63 Announce Licensing Agreement 63 PDUFA Date 63 Completes Purchase Of 63 Reaches Agreements 63 Extends Expiration Date 63 Patient Treated 63 Bladex Announces 63 Streamlines Operations 63 Expand Collaboration 63 Annual Meeting Date 62 Implantable Defibrillators 62 Receives Accreditation 62 Announce Expiration 62 4Q Profit Dips 62 Shows Promise Against 62 Clears Path 62 Declares Preferred Dividends 62 Q1 Profit Plunges 62 Obtains Exclusive Rights 62 Debt Tender Offers 62 4Q Loss Narrows 62 Completes Recapitalization 62 Announce Receipt 62 Newly Identified 62 Geokinetics Announces 62 Study Reinforces 62 Previously Disclosed 62 Closes Previously Announced 62 Narrows Guidance 62 Restate Financials 62 Restate Financial 62 Stockholders Approve Acquisition 62 Closes Sale 62 Flagstone Re Announces 62 Vertebral Fractures 62 Enters Into Definitive Agreement 62 Heartburn Drugs 62 Q4 Profit Soars 62 Miraculins Announces 62 Posts 4Q 62 Drug Coated Stent 62 BioElectronics Announces 62 Gout Drug 62 Initiates Phase II 62 Presents Positive 62 Amend Merger Agreement 62 Appears Safe 62 Pain Relievers 62 Declares Quarterly Dividends 62 Enrolls First 62 Closes Acquisition Of 62 Nanophase Announces 62 Stereotaxis Announces 62 Guides Inline 62 Voluntary Recall 62 Teva Provides Update 62 Receives CE Marking 62 Crowflight Announces 62 Sign Licensing Agreement 62 Announces Underwriters Exercise 62 Heart Stents 62 Launches Generic Version 62 Achieves Record Sales 62 Test Detects 62 Exploring Strategic Alternatives 62 Significantly Improves 62 Submits IND 62 Bagged Spinach 62 Q4 Profit Surges 62 Announces Discontinuation 62 Posts 4Q Profit 62 Improves Outcomes 62 Underscores Importance 62 Metabolic Disorder 62 Initiates Clinical 62 Announces Rebranding 62 Closes Buyout 62 Holds Annual Meeting 62 Lowers Risk 62 Prompt Recall 62 Nicotine Vaccine 62 Receives Requisite Consents 62 Posts Wider 4Q Loss 62 Evaluate Strategic Alternatives 62 Announces Favorable 62 Sign Definitive Agreement 62 Neutral Analyst Blog 62 2Q Profit Soars 62 Finalize Agreement 62 Settle Lawsuits 62 Finalizes Purchase Of 62 Fungal Infections 62 Cholesterol Drugs 62 Receives Clearance 62 Previously Announced 62 Commences Offering 62 Releases Third Quarter 62 3Q Profit Plunges 62 Hikes Dividend 62 Announces Job Cuts 62 Acquire Assets 62 Reduces Workforce 62 Becomes Effective 62 Q4 Adj 62 Q2 Profit Surges 62 Acknowledges Receipt 62 Reschedules Fourth Quarter 62 Recommends Changes 62 Contaminant Found 62 Reconfirms 62 Announces Shareholder Approval 62 Pending Acquisition 62 Licenses Patents 62 Jointly Announce 62 Crib Recall 62 Narrows Loss 62 Confirms Efficacy 62 Hires Lobbyist 62 Taglich Brothers Initiates Coverage 62 CFO Resigns 62 Poniard Pharmaceuticals Announces 62 Q4 Profit Drops 62 Boosts Buyback 62 Concludes Acquisition 62 Receives Tentative Approval 62 Directors Unanimously Rejects 62 Posts 2Q Profit 62 Reports 4Q Loss 62 Announces Affiliation 62 Signs Purchase Agreement 62 Workforce Reduction 62 VIVUS Announces 62 Peanut Butter Recall 62 Remains Neutral 62 Lifts FY# Guidance 62 Generic Versions 62 Helps Prevent 62 Receives NASDAQ 62 Announces License Agreement 62 Renews Agreement 61 Cholesterol Drug 61 Warrants Exercised 61 Posts Narrower Loss 61 Anemia Drug 61 Proxy Proposals 61 Subsidiaries Consolidated Statement 61 Reaffirms Fourth Quarter 61 Receives Authorization 61 Completes Asset 61 Expanded Indication 61 Re Affirms 61 Shareholders Approve Proposed 61 Earns Milestone Payment 61 Stockholders Approve Merger Agreement 61 Announces Licensing Agreement 61 Completes Redemption 61 Resubmit 61 Cribs Recalled 61 Statement Regarding 61 Revises Fourth Quarter 61 Provides Clarification 61 3Q Profit Jumps 61 1Q Profit Slides 61 4Q Profit Slips 61 Announces Initiation 61 Restate Results 61 Significantly Expand 61 Extends Collaboration 61 Withdraws Proposal 61 Drug Candidate 61 Commences Cash 61 Procedure Kits 61 Announces Profitable 61 Omnicare Declares Quarterly 61 Successfully Treats 61 Completes Debt Refinancing 61 Posts 1Q Profit 61 Q1 Profit Soars 61 Resubmission 61 Awarded Contract Extension 61 Posts 2Q 61 Patient Enrollment 61 Shingles Vaccine 61 reaffirms FY# outlook 61 Secures Financing 61 Completes Purchase 61 Lowers Outlook 61 Q2 Profit Drops 61 Complete Merger 61 Delays Filing 61 Announce Settlement 61 Increases Size 61 Reveals Receipt 61 Obtains Patent 61 Restate Earnings 61 Outlines Strategy 61 Significantly Reduced 61 Heart Transplant Recipients 61 Demonstrates Commitment 61 Reaffirms FY# Guidance 61 Proposed Offering 61 Unveils Groundbreaking 61 Boosts Outlook 61 ANADIGICS Announces 61 Terminates Merger Agreement 61 Integra LifeSciences Announces 61 ESCO Announces 61 Realigns 61 Announces Tentative Approval 61 Collaborators Present 61 Receives Orphan Drug 61 Delivers Solid 61 Receives Notice 61 Q2 Profit Slips 61 Reduces Mortality 61 Projected Release Date 61 Blood Thinner 61 Strollers Recalled 61 H.B. Fuller 61 NPS Pharmaceuticals Announces 61 Commences Consent Solicitation 61 Reports Profitable 61 Selects BoardVantage 61 Investigational Treatment 61 Retains Leading 61 Completes Integration 61 Reports Narrower Loss 61 Hires Experienced 61 Data Suggest 61 Asthma Treatment 61 Reveals Positive 61 Derma Sciences Announces 61 Shows Promising 61 Phase 2b Trial 61 Osteoporosis Drug 61 Q2 Profit Plunges 61 Restructures Operations 61 Reduced Risk 61 KEMET Announces 61 Wizzard Software Announces 61 Mylan Receives Approval 61 Confirms Receipt 61 Patent Infringement Lawsuit 61 Gets Approval 61 Reinforces Importance 61 Monetizes 61 Reports Significantly Improved 61 Study Recommends 61 Q2 Profit Soars 61 Receives Confirmation 61 Announces Dismissal 61 Announces Resumption 61 Helps Detect 61 Antiviral Drugs 61 Announces Issuance 61 Achieves Positive 61 WebTech Wireless Announces 61 Settle Patent Litigation 61 Subsidiary Files 61 Stock Soars 61 Declares Dividend Increase 61 Web Site http:/www.cryolife.com 61 Successfully Completes Phase 61 Newmont Declares Regular 61 Withdraws Application 61 Suit Settled 61 Issues Voluntary Recall 61 Commences Phase 61 1Q Loss Narrows 61 Acquire Privately Held 61 Announce Commencement 61 Less Invasive 61 Q1 Profit Dips 61 Announces Definitive Agreements 61 Authorizes Repurchase 61 Terminate Merger Agreement 61 Announce Shareholder Approval 61 Commences Tender Offer 61 Clinical Trial Evaluating 61 Milestone Reached 61 Sees Decline 61 IND Application 61 OKs Buyback 61 4Q Profit Surges 61 Shows Efficacy 61 Review Strategic Alternatives 61 Receives Approval From 61 Shareholders Approve Merger Agreement 61 Shareholder Opposes 61 Successfully Concludes 61 Lifts FY# Outlook 61 Completes Acquisitions 61 SulphCo Announces 61 Completes Expansion 61 Patent Infringement Suit 61 Posts 1Q 61 Study Indicates 61 Q1 Profit Drops 61 Study Shows Significant 61 Posts Third Quarter 61 First Patient Enrolled 61 Approve Merger 61 Demonstrates Ability 61 Deemed Safe 61 Announces Adjournment 60 Clarifies Status 60 Reaffirms FY# Outlook 60 Announces Termination 60 Obtains CE Mark 60 Settles Patent Dispute 60 Halts Sale 60 Ups Guidance 60 Empowers Consumers 60 Announces Conditional Approval 60 Could Save Lives 60 Patent Lawsuit Against 60 Q1 Profit Declines 60 Unsolicited Proposal 60 Issues Reminder 60 Posts Fourth Quarter 60 Doubles Size 60 Posts Wider 60 XPEL Announces 60 PHAZAR CORP Announces 60 Welcomes Analyst Initiation 60 Arthritis Drugs 60 Announce Early Termination 60 Stockholders Approve 60 Inhaled Insulin 60 Study Analyzes 60 Settle Patent Dispute 60 Ephedra Ban 60 2Q Profit Slides 60 Generic Version 60 Migraine Drug 60 Feds Warn 60 Submits Investigational 60 Taro Receives 60 1Q Profit Down 60 Completes Private Placement 60 Posts Wider 2Q 60 Announce Completion 60 Lifts Dividend 60 Cholesterol Lowering Drug 60 4Q Profit Doubles 60 Celebrates Completion 60 Extends Offer 60 Secures Long Term 60 Significantly Reduces 60 TOP Ships Announces 60 Phase 2a Trial 60 Key Milestones 60 Anti Clotting Drug 60 1Q Profit Falls 60 Renegotiates 60 Reports Narrower 60 Receives Fast Track 60 Renews Lease 60 Finalizes Sale Of 60 Reduces Size 60 Present Preclinical Data 60 Formalizes 60 Commences Initial 60 Announces Additions 60 4Q Profit Soars 60 Relocates Corporate Headquarters 60 Earnings Postmortem 60 Q3 Profit Surges 60 Voluntary Withdrawal 60 Receives URAC Accreditation 60 Presents Positive Preclinical 60 Upcoming Conferences 60 Demonstrates Statistically Significant 60 Granted Orphan Drug 60 Strengthens Position 60 Files Petition 60 Preliminary Injunction Against 60 Being Evaluated 60 FDA Warns Against 60 Device Helps 60 ZTEST Announces 60 Shareholders Approve Proposals 60 Extends Term 60 Q2 Profit Declines 60 Announces Refinancing 60 Epilepsy Drugs 60 Lawsuit Filed Against 60 Genes Identified 60 Updates Status 60 Share Repurchases 60 Hold Fourth Quarter 60 Sinus Infections 60 Univest Corporation Declares 60 Issues Statement Regarding 60 Settle Suit Over 60 Signs Licensing Agreement 60 Adverse Event 60 Demonstrates Positive 60 Amends Merger Agreement 60 Gene Variants 60 Announces Reverse Split 60 Announces Commencement 60 Receives Notification From 60 Exits Bankruptcy 60 Fourth Quarter Profit Drops 60 Temporarily Suspend 60 HCV Protease Inhibitor 60 Clinical Trial Results 60 Study Validates 60 Underscores Commitment 60 3Q Profit Drops 60 Approvable 60 FY# Guidance 60 Could Prevent 60 Recalls Peanut Butter 60 Announce Licensing 60 Previously Announced Private Placement 60 Jumps Higher 60 Receives Conditional 60 Announces Receipt 60 BioElectronics Corporation Announces 60 1Q Profit Climbs 60 Announces Partial Redemption 60 Helps Identify 60 Spectrum Pharmaceuticals Announces 60 Postpones Annual Meeting 60 Renews Expands 60 Generic Version Of 60 Non Infringement 60 Recommends Approval 60 Data Indicate 60 Considers Sale 60 Announces Presentation 60 Subsidiary Enters 60 Q1 Profit Slips 60 Increases Cash Dividend 60 Being Studied 60 Sets Annual Meeting 60 Initiates Quarterly 60 Stock Buyback Program 60 Medoro Resources Announces 60 Lung Cancer Drug 60 Underwritten Public 60 Smallpox Vaccine 60 4Q Profit Jumps 60 Reminds Consumers 60 Obtains License 60 Lawsuits Filed 60 Protein Synthesis 60 Cost Reductions 60 1Q Profit Dips 60 Submits Revised 60 2Q Profit Drops 60 Increases Quarterly Cash Dividend 60 Receives Regulatory 60 Suit Alleges 60 Webcast Annual Meeting 60 Webcast Presentations 60 Commenced Against 60 Q1 Profit Surges 60 Receives Complete Response 60 Reaffirms Earnings 60 Reveals Significant 60 Settles Charges 60 Initiates Phase III 60 Obtains Financing 60 Morphine Sulfate 60 Q4 Profit Plunges 60 Zynex Announces 60 Mutually Agree 60 Furthers Commitment 60 Vascular Grafts 60 Effectively Treats 60 Provides Shareholder 60 Pending Merger 60 Awarded Patent 60 Announce Successful Completion 60 IG HCR ;) CO 60 Similac Recall 60 Q4 Profit Declines 60 LightPath Technologies Announces 60 Announcement Regarding 60 Minimally Invasive Procedure 60 Sees Wider 60 Amends Terms 60 Regulatory Filing 60 Continues Aggressive 60 Restricts Access 60 Phase IIb Clinical Trial 60 Backs FY# View 60 Announces Debt Settlement 60 Releases Second Quarter 60 Milestone Payments 60 Expands Relationship With 60 Terminate Agreement 60 Subsidiary Completes 60 Seek Shareholder Approval 60 Recall Expands 60 Mulls Sale 60 Expects Higher 60 Therapeutic Competitors Report 60 Upside Looming 59 Sustained Reduction 59 Reaches Tentative Settlement 59 Files Amended 59 Demonstrates Sustained 59 HSR Waiting Period 59 Reaches Settlement Agreement 59 Has Commenced 59 Adjourns Special Meeting 59 Q3 Profit Declines 59 Provides Updates 59 Biologics Manufacturing 59 Sony Laptop Batteries 59 Experts Advise 59 Patent Expirations 59 Completes Successful 59 Oral Calcitonin 59 Lawsuit Alleging 59 L.P. Announces 59 Announces Effectiveness 59 Combination Treatment 59 First Patient Treated 59 Regains Compliance 59 Panel Endorses 59 Anworth Announces 59 Successfully Completes Acquisition 59 Workers Ratify Contract 59 Experts Warn Against 59 Expert Offers Tips 59 Announces Favorable Ruling 59 Stock Buyback Plan 59 CFO Exercises Options 59 Signs Agreements 59 Kidney Transplant Patients 59 Announces Intent 59 Introduces Breakthrough 59 Stock Plunges 59 Regains Compliance With 59 NYSE Amex Listing 59 Rheumatoid Arthritis Drug 59 Commonly Prescribed 59 Announces Debt Refinancing 59 Results Confirm 59 Wins Patent Infringement 59 Host Teleconference 59 4Q Profit Rises 59 Receives Regulatory Approvals 59 Reach Settlement Agreement 59 Possible Contamination 59 Broadens Its 59 VP Exercises Options 59 Treatment Resistant 59 Receives SFDA Approval 59 Unapproved Drugs 59 Declares Preferred 59 Fentanyl Patch 59 Resubmits 59 Enters Into Definitive 59 Commence Immediately 59 Commence Tender Offer 59 Flavored Cigarettes 59 Knee Implant 59 Reports Sharply Higher 59 Study Showed 59 Successfully Treated 59 Beats Estimates Analyst Blog 59 Boosts Quarterly Dividend 59 Cell Phone Batteries 59 Revises Earnings 59 Announces Appointments 59 Settles Dispute 59 Hold Third Quarter 59 Receives Patent 59 Help Detect 59 Retains CCG Investor Relations 59 Files Definitive Proxy 59 Provides Preliminary 59 Non Invasive Treatment 59 Prolongs Survival 59 FDA Approves 59 Underscores Need 59 KB Home Swings 59 Concerns Arise 59 FDA Approves Generic 59 Folding Chairs 59 Helps Ensure 59 CEO Exercises Options 59 Announces Proposed Settlement 59 Unveils Revolutionary 59 Schedules Fourth Quarter Earnings 59 Revenues Decline 59 Receives Clearance From 59 Buyout Offer 59 Correlation Between 59 Delivers Unprecedented 59 Gentex Declares Quarterly 59 Declares Increase 59 Drug Coated Stents 59 Acquires Controlling Interest 59 Explores Options 59 Selects Trintech 59 Announces Proposed Acquisition 59 Clarification Regarding 59 Introduces Enhanced 59 Drug Makers 59 Gene Expression Analysis 59 2Q Profit Up 59 Patents Covering 59 Announce Collaboration Agreement 59 Blood Clot Risk 59 Q3 Profit Rises 59 Risk Warning 59 Demonstrates Potential 59 Launches Redesigned Website 59 Reduces Pain 59 Enters Negotiations 59 Balance Sheet Restructuring 59 Q3 Profit Soars 59 3Q Profit Rises 59 Q4 Profit Slips 59 Cell Transplants 59 Receives Anticipated 59 Flu Vaccines 59 Ups Dividend 59 Develop Novel 59 Expands Commitment 59 Schizophrenia Drug 59 Profit Dips 59 Posts Smaller 59 Surgical Procedures 59 Reports Receipt 59 ΞΕΝΗ ΔΗΜΟΣΙΕΥΣΗ ΑΝΑΚΟΙΝΩΣΗInfosys Finacle 59 Authorizes Additional 59 Amends Credit 59 SWOT Analysis Aarkstore Enterprise 59 Tablet Formulation 59 Issues Surrounding 59 Drug Prevents 59 Toys Recalled 59 Subsidiaries Supplemental 59 Announces Enhancements 59 Voluntarily Delist 59 Emphasizes Need 59 Announce Filing 59 Files Resale 59 Asthma Inhalers 59 4Q Profit Drops 59 Pivotal Clinical Trial 59 4Q Profit Down 59 Funds Announce 59 Acquires Assets 59 Implant Sciences Announces 59 Declares Quarterly Common 59 Boosts Dividend 59 Presents Preclinical Data 59 Reprices 59 CFO Steps Down 59 Sells Shares 59 1Q Profit Jumps 59 Weight Loss Drug 59 Sets Earnings Release 59 Successfully Complete 59 Directors Authorizes 59 2Q Profit Down 59 Antipsychotic Drug 59 Liver Toxicity 59 Achieves Unprecedented 59 Increases Quarterly 59 Expert Discusses 59 Submits Supplemental 59 Protein Linked 59 Completes Spin Off 59 Earns Recognition 59 Commences Phase III 59 Pivotal Trial 59 Receives Conditional Approval 59 3Q Profit Declines 59 Receives Tentative FDA 59 Commercializes 59 Genetic Tests 59 Assets Acquirer Company 59 Deaths Linked 59 Statin Drugs 59 Announces Tender Offers 59 Posts Wider 3Q 59 WorldHeart Announces 59 Engages CHF Investor Relations 59 Predict Dementia 59 Shareholders Approve Increase 59 Bearish MACD 59 Sees 3Q 59 Receives Notice From 59 Meets Primary Endpoint 59 Spinal Fusion 59 Doubles Capacity 59 Inc. www.coopersurgical.com develops 59 Net Loss Widens 59 Schizophrenia Treatment 59 Bush Embraces Pause 59 Earns Certification 59 Clinical Study Shows 59 Backs FY# Guidance 59 Profit Beats Expectations 59 Executes Agreements 59 FY# Loss Narrows 59 Single Dose 59 Questions Remain About 59 Signs Definitive Agreement 59 Voluntarily Recalled 59 Makes Announcement 59 Reports Preclinical Data 59 Releases Statement Regarding 59 Nasdaq Delisting 59 Suit Challenging 59 Prove Effective 59 4Q Profit Plunges 59 Beats Raises Guidance 59 Has Been Awarded 59 Declares Fourth Quarter 59 Celebrates Opening 59 Signs Option Agreement 59 Nasdaq Deficiency Notice 59 First BanCorp Announces 59 Similac Formula 59 Antibiotic Treatment 59 Announce Initiation 58 Improves Patient 58 Reaches Pact 58 Its Previously Announced 58 Patents Issued 58 Option Grants 58 Expand Relationship 58 Broadens Scope 58 Warning Issued 58 Prostate Cancer Vaccine 58 Restates 58 Breast Cancer Recurrence 58 GeoMet Announces 58 BIOLASE Announces 58 Muscle Wasting 58 Pending Litigation 58 Directors Elects 58 Moderate Drinking 58 Director Exercises Options 58 Infusion Pumps 58 Inks Licensing Deal 58 Lawsuit Filed Over 58 Investigation Relating 58 Significant Reduction 58 Exec Exercises Options 58 Shelf Registration Statement 58 Cold Medicines 58 Study Proves 58 Million Dishwashers 58 Significantly Increases 58 Profit Tops Estimates 58 Successfully Closes 58 Completes Restatement 58 Cancels Planned 58 Assumes Responsibility 58 Posts 2Q Loss 58 Positively Impacts 58 Achieves Primary Endpoint 58 Phase III Trial 58 Posts Wider Than Expected 58 Study Compares 58 Cuts Threaten 58 Treatment Reduces 58 Faces Setback 58 2Q Profit Climbs 58 Phase 2b Clinical Trial 58 Achieves Record Results 58 Lays Off Workers 58 Q4 Profit Climbs 58 Receives Permit 58 Earnings Scorecard 58 Favorable Decision 58 Retinal Diseases 58 Reports 2Q Profit 58 Antipsychotic Drugs 58 Withdraws Offer 58 Complies With 58 Shareholder Sues 58 Receives Funding 58 Exercises Option